Review





Similar Products

96
Proteintech mouse anti tlr4
Mouse Anti Tlr4, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/TLR4+Antibody/pm42867288-69-43-45
Average 96 stars, based on 1 article reviews
mouse anti tlr4 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

97
ABclonal Biotechnology mouse anti tlr4 antibody
Oral SH inhibited the <t>TLR4/MyD88/NF-κB</t> signaling pathways both in the SN and the colon of MPTP-induced mice. ( A ) Schematic representation of the signaling pathway. ( B ) Representative WB bands of TLR4, MyD88, and NF-κB in the colon. ( C ) Representative WB bands of TLR4, MyD88, and NF-κB in the midbrain containing the SN. ( D – F ) The density analysis results of TLR4, MyD88, and NF-κB in the colon. ( G – I ) The density analysis results of TLR4, MyD88, and NF-κB in the midbrain containing the SN. ( n = 3 for each group. Data are presented as mean ± SD. *** p < 0.001 versus the control group; ### p < 0.001 versus the MPTP group.).
Mouse Anti Tlr4 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/TLR4+Rabbit+pAb/pmc13466556-237-60-65
Average 97 stars, based on 1 article reviews
mouse anti tlr4 antibody - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

93
R&D Systems recombinant mouse tlr4
eCasp-1 binds to <t>TLR4</t> to drive inflammation, which is effectively suppressed by the novel peptide C16. (A, B) Computational modeling predicted a strong interaction between eCasp-1 (red) and TLR4 (blue). (C) SPR analysis on the binding of eCasp-1 to TLR4 in vitro . (D, E) WT and TLR4 -/- peritoneal macrophages were treated with PBS or eCasp-1 (0.1 µg/ml) for 4 h. (D) IL-6 and (E) TNFα levels in the supernatants were measured by ELISA. (F, G) WT and TLR4 -/- mice received i.p. injections of PBS or eCasp-1 (5 µg/g BW), and plasma was collected 24 h later to measure (F) IL-6 and (G) TNFα. (H) In-silico analysis identified a putative binding site for mouse eCasp-1 (red) on the extracellular domain of TLR4 (blue). (I) C16 (silver), a 16-amino-acid peptide mimic, was designed based on the predicted binding interface and exhibited strong binding to eCasp-1 (red). (J) Computational modeling predicted a potential interaction between the eCasp-1-C16 complex and TLR4. (K) SPR analysis of eCasp-1 binding to TLR4 in the presence or absence of C16. (L) WT peritoneal macrophages were treated with eCasp-1 (0.1 µg/mL) with increasing concentrations of C16 (0.1, 1, 10 µg/mL) for 4 h, and TNFα levels in the supernatants were measured by ELISA. Experiments were repeated 2–3 times and all the data obtained were used for analysis. Data were expressed as mean ± SEM (n = 5–9 samples/group) and compared by one-way analysis of variance and Student-Newman-Keuls method ( * p < 0.05 vs. WT PBS; # p < 0.05 vs. WT with eCasp-1, (+)eCasp-1 (-)C16).
Recombinant Mouse Tlr4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/Recombinant+Mouse+TLR4+Fc+Chimera+Protein%2C+CF/pmc13124943-69-0-9
Average 93 stars, based on 1 article reviews
recombinant mouse tlr4 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
Proteintech mouse anti ppara
eCasp-1 binds to <t>TLR4</t> to drive inflammation, which is effectively suppressed by the novel peptide C16. (A, B) Computational modeling predicted a strong interaction between eCasp-1 (red) and TLR4 (blue). (C) SPR analysis on the binding of eCasp-1 to TLR4 in vitro . (D, E) WT and TLR4 -/- peritoneal macrophages were treated with PBS or eCasp-1 (0.1 µg/ml) for 4 h. (D) IL-6 and (E) TNFα levels in the supernatants were measured by ELISA. (F, G) WT and TLR4 -/- mice received i.p. injections of PBS or eCasp-1 (5 µg/g BW), and plasma was collected 24 h later to measure (F) IL-6 and (G) TNFα. (H) In-silico analysis identified a putative binding site for mouse eCasp-1 (red) on the extracellular domain of TLR4 (blue). (I) C16 (silver), a 16-amino-acid peptide mimic, was designed based on the predicted binding interface and exhibited strong binding to eCasp-1 (red). (J) Computational modeling predicted a potential interaction between the eCasp-1-C16 complex and TLR4. (K) SPR analysis of eCasp-1 binding to TLR4 in the presence or absence of C16. (L) WT peritoneal macrophages were treated with eCasp-1 (0.1 µg/mL) with increasing concentrations of C16 (0.1, 1, 10 µg/mL) for 4 h, and TNFα levels in the supernatants were measured by ELISA. Experiments were repeated 2–3 times and all the data obtained were used for analysis. Data were expressed as mean ± SEM (n = 5–9 samples/group) and compared by one-way analysis of variance and Student-Newman-Keuls method ( * p < 0.05 vs. WT PBS; # p < 0.05 vs. WT with eCasp-1, (+)eCasp-1 (-)C16).
Mouse Anti Ppara, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/TLR4+Antibody/pm41905731-154-42-45
Average 96 stars, based on 1 article reviews
mouse anti ppara - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech anti tlr4 mouse
eCasp-1 binds to <t>TLR4</t> to drive inflammation, which is effectively suppressed by the novel peptide C16. (A, B) Computational modeling predicted a strong interaction between eCasp-1 (red) and TLR4 (blue). (C) SPR analysis on the binding of eCasp-1 to TLR4 in vitro . (D, E) WT and TLR4 -/- peritoneal macrophages were treated with PBS or eCasp-1 (0.1 µg/ml) for 4 h. (D) IL-6 and (E) TNFα levels in the supernatants were measured by ELISA. (F, G) WT and TLR4 -/- mice received i.p. injections of PBS or eCasp-1 (5 µg/g BW), and plasma was collected 24 h later to measure (F) IL-6 and (G) TNFα. (H) In-silico analysis identified a putative binding site for mouse eCasp-1 (red) on the extracellular domain of TLR4 (blue). (I) C16 (silver), a 16-amino-acid peptide mimic, was designed based on the predicted binding interface and exhibited strong binding to eCasp-1 (red). (J) Computational modeling predicted a potential interaction between the eCasp-1-C16 complex and TLR4. (K) SPR analysis of eCasp-1 binding to TLR4 in the presence or absence of C16. (L) WT peritoneal macrophages were treated with eCasp-1 (0.1 µg/mL) with increasing concentrations of C16 (0.1, 1, 10 µg/mL) for 4 h, and TNFα levels in the supernatants were measured by ELISA. Experiments were repeated 2–3 times and all the data obtained were used for analysis. Data were expressed as mean ± SEM (n = 5–9 samples/group) and compared by one-way analysis of variance and Student-Newman-Keuls method ( * p < 0.05 vs. WT PBS; # p < 0.05 vs. WT with eCasp-1, (+)eCasp-1 (-)C16).
Anti Tlr4 Mouse, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/TLR4+Antibody/pm41888318-226-15-19
Average 96 stars, based on 1 article reviews
anti tlr4 mouse - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology mouse anti tlr4 antibody
Nr-CWS affects MARCO expression through <t>TLR4.</t> The expression of TLR4 significantly increased after Nr-CWS treatment [ (D-G) , scale bars = 100 μm], while the expression TLR2 was unchanged (A-C) . Subsequent inhibition of TLR4 expression resulted in decreased levels of MARCO [ (H-J) , scale bars = 100 μm]. n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001.
Mouse Anti Tlr4 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/TLR4+Antibody/pmc12936005-236-56-59
Average 96 stars, based on 1 article reviews
mouse anti tlr4 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc mouse monoclonal anti tlr4 antibody
EA-induced analgesia is associated with MD2, <t>TLR4,</t> and p-p65/p65 in the ST36 acupoint and MD2 and TLR4 interactions. (A) The experimental protocol timeline is illustrated, with the duration of each intervention clearly indicated in the figure. (B) The location of the ST36 acupoint in mice (up) and the swelling of paw comparison before (right) and after (left) CFA injection. (C) PTWTs were detected on the D-3 to D-1, D1pre, D1post, D3, D5, and D7 after interventions (n = 8), ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM. (D) The expression levels of PKC protein in the spinal cord were determined by WB (n = 3), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (E, F) The expression levels of CX3CL1 (E) , IL-1β (F) in the spinal cord were determined by Elisa (n = 6), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (G) Data sourced from https://cn.string-db.org/ . (H) Co-IP assay with TLR4 antibody (or IgG) in the ST36 acupoint, followed by WB analysis of MD2 and TLR4. (I–K) The expression levels of MD2 (I) , TLR4 (J) , and p-p65/p65 (K) were determined using WB analysis in the ST36 acupoint on D7 (n = 3), * P < 0.05 vs. the CON, ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM.
Mouse Monoclonal Anti Tlr4 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/pmc12893965-101-12-26
Average 86 stars, based on 1 article reviews
mouse monoclonal anti tlr4 antibody - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology mouse anti tlr4
EA-induced analgesia is associated with MD2, <t>TLR4,</t> and p-p65/p65 in the ST36 acupoint and MD2 and TLR4 interactions. (A) The experimental protocol timeline is illustrated, with the duration of each intervention clearly indicated in the figure. (B) The location of the ST36 acupoint in mice (up) and the swelling of paw comparison before (right) and after (left) CFA injection. (C) PTWTs were detected on the D-3 to D-1, D1pre, D1post, D3, D5, and D7 after interventions (n = 8), ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM. (D) The expression levels of PKC protein in the spinal cord were determined by WB (n = 3), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (E, F) The expression levels of CX3CL1 (E) , IL-1β (F) in the spinal cord were determined by Elisa (n = 6), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (G) Data sourced from https://cn.string-db.org/ . (H) Co-IP assay with TLR4 antibody (or IgG) in the ST36 acupoint, followed by WB analysis of MD2 and TLR4. (I–K) The expression levels of MD2 (I) , TLR4 (J) , and p-p65/p65 (K) were determined using WB analysis in the ST36 acupoint on D7 (n = 3), * P < 0.05 vs. the CON, ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM.
Mouse Anti Tlr4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+tlr4/TLR4+Antibody/pmc12733209-257-28-31
Average 96 stars, based on 1 article reviews
mouse anti tlr4 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


Oral SH inhibited the TLR4/MyD88/NF-κB signaling pathways both in the SN and the colon of MPTP-induced mice. ( A ) Schematic representation of the signaling pathway. ( B ) Representative WB bands of TLR4, MyD88, and NF-κB in the colon. ( C ) Representative WB bands of TLR4, MyD88, and NF-κB in the midbrain containing the SN. ( D – F ) The density analysis results of TLR4, MyD88, and NF-κB in the colon. ( G – I ) The density analysis results of TLR4, MyD88, and NF-κB in the midbrain containing the SN. ( n = 3 for each group. Data are presented as mean ± SD. *** p < 0.001 versus the control group; ### p < 0.001 versus the MPTP group.).

Journal: International Journal of Molecular Sciences

Article Title: Oral Sodium Hyaluronate Reshapes Gut Microbiota Composition and Suppresses the LPS-TLR4/NF-κB Pathway to Exert Neuroprotection in MPTP-Induced Parkinson’s Disease

doi: 10.3390/ijms27156573

Figure Lengend Snippet: Oral SH inhibited the TLR4/MyD88/NF-κB signaling pathways both in the SN and the colon of MPTP-induced mice. ( A ) Schematic representation of the signaling pathway. ( B ) Representative WB bands of TLR4, MyD88, and NF-κB in the colon. ( C ) Representative WB bands of TLR4, MyD88, and NF-κB in the midbrain containing the SN. ( D – F ) The density analysis results of TLR4, MyD88, and NF-κB in the colon. ( G – I ) The density analysis results of TLR4, MyD88, and NF-κB in the midbrain containing the SN. ( n = 3 for each group. Data are presented as mean ± SD. *** p < 0.001 versus the control group; ### p < 0.001 versus the MPTP group.).

Article Snippet: Membranes were incubated at 4 °C overnight with the following primary antibodies: rabbit anti-β-actin antibody (1:50,000, AC026, Abclonal, Wuhan, China), mouse anti-TH antibody (1:1000, A0028, Abclonal, Wuhan, China), rabbit anti-TNF-α antibody (1:1000, A20851, Abclonal, Wuhan, China), rabbit anti-IL-1β antibody (1:1000, A11369, Abclonal, Wuhan, China), rabbit anti-IL-6 antibody (1:1000, A0286, Abclonal, Wuhan, China), goat anti-COX-2 antibody (1:1000, A1253, Abclonal, Wuhan, China), mouse anti-TLR4 antibody (1:1000, A5258, Abclonal, Wuhan, China), rabbit anti-MyD88 antibody (1:400, A0980, Abclonal, Wuhan, China), rabbit anti-IκB-α antibody (1:1000, A24742, Abclonal, Wuhan, China), rabbit anti-ZO-1 antibody (1:1000, A0659, Abclonal, Wuhan, China), mouse anti-claudin-1 antibody (1:1000, Abclonal, Wuhan, China), rabbit anti-occludin antibody (1:1000, Abclonal, China), and mouse anti-claudin-5 antibody (1:1000, A10207 , Abclonal, Wuhan, China).

Techniques: Protein-Protein interactions, Control

eCasp-1 binds to TLR4 to drive inflammation, which is effectively suppressed by the novel peptide C16. (A, B) Computational modeling predicted a strong interaction between eCasp-1 (red) and TLR4 (blue). (C) SPR analysis on the binding of eCasp-1 to TLR4 in vitro . (D, E) WT and TLR4 -/- peritoneal macrophages were treated with PBS or eCasp-1 (0.1 µg/ml) for 4 h. (D) IL-6 and (E) TNFα levels in the supernatants were measured by ELISA. (F, G) WT and TLR4 -/- mice received i.p. injections of PBS or eCasp-1 (5 µg/g BW), and plasma was collected 24 h later to measure (F) IL-6 and (G) TNFα. (H) In-silico analysis identified a putative binding site for mouse eCasp-1 (red) on the extracellular domain of TLR4 (blue). (I) C16 (silver), a 16-amino-acid peptide mimic, was designed based on the predicted binding interface and exhibited strong binding to eCasp-1 (red). (J) Computational modeling predicted a potential interaction between the eCasp-1-C16 complex and TLR4. (K) SPR analysis of eCasp-1 binding to TLR4 in the presence or absence of C16. (L) WT peritoneal macrophages were treated with eCasp-1 (0.1 µg/mL) with increasing concentrations of C16 (0.1, 1, 10 µg/mL) for 4 h, and TNFα levels in the supernatants were measured by ELISA. Experiments were repeated 2–3 times and all the data obtained were used for analysis. Data were expressed as mean ± SEM (n = 5–9 samples/group) and compared by one-way analysis of variance and Student-Newman-Keuls method ( * p < 0.05 vs. WT PBS; # p < 0.05 vs. WT with eCasp-1, (+)eCasp-1 (-)C16).

Journal: Frontiers in Immunology

Article Title: Extracellular caspase-1: a critical inducer and a therapeutic target of lung injury in gut ischemia-reperfusion

doi: 10.3389/fimmu.2026.1811868

Figure Lengend Snippet: eCasp-1 binds to TLR4 to drive inflammation, which is effectively suppressed by the novel peptide C16. (A, B) Computational modeling predicted a strong interaction between eCasp-1 (red) and TLR4 (blue). (C) SPR analysis on the binding of eCasp-1 to TLR4 in vitro . (D, E) WT and TLR4 -/- peritoneal macrophages were treated with PBS or eCasp-1 (0.1 µg/ml) for 4 h. (D) IL-6 and (E) TNFα levels in the supernatants were measured by ELISA. (F, G) WT and TLR4 -/- mice received i.p. injections of PBS or eCasp-1 (5 µg/g BW), and plasma was collected 24 h later to measure (F) IL-6 and (G) TNFα. (H) In-silico analysis identified a putative binding site for mouse eCasp-1 (red) on the extracellular domain of TLR4 (blue). (I) C16 (silver), a 16-amino-acid peptide mimic, was designed based on the predicted binding interface and exhibited strong binding to eCasp-1 (red). (J) Computational modeling predicted a potential interaction between the eCasp-1-C16 complex and TLR4. (K) SPR analysis of eCasp-1 binding to TLR4 in the presence or absence of C16. (L) WT peritoneal macrophages were treated with eCasp-1 (0.1 µg/mL) with increasing concentrations of C16 (0.1, 1, 10 µg/mL) for 4 h, and TNFα levels in the supernatants were measured by ELISA. Experiments were repeated 2–3 times and all the data obtained were used for analysis. Data were expressed as mean ± SEM (n = 5–9 samples/group) and compared by one-way analysis of variance and Student-Newman-Keuls method ( * p < 0.05 vs. WT PBS; # p < 0.05 vs. WT with eCasp-1, (+)eCasp-1 (-)C16).

Article Snippet: Recombinant mouse TLR4 (rmTLR4; ≥90% purity) was purchased from R&D Systems (Cat. No. 9149-TR-050, Minneapolis, MN), supplied in carrier-free form, and reconstituted in sterile PBS according to the manufacturer’s instructions.

Techniques: Binding Assay, In Vitro, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, In Silico

Summary of findings. In gut I/R injury, inflammasomes activation promotes the cleavage of caspase-1 and the extracellular release of its p20 subunit through GSDMD-dependent membrane processes. This release may occur in association with GSDMD pore formation as well as membrane disruption during lytic cell death (pyroptosis). Once released, extracellular caspase-1 (eCasp-1) acts as a potent DAMP by binding to TLR4, thereby amplifying release of inflammatory cytokines, aggravating lung injury. Therapeutic intervention with the inhibitory peptide C16, which specifically blocks the eCasp-1-TLR4 interaction, effectively attenuates systemic inflammation and improves survival outcomes. I/R, Ischemia-reperfusion; GSDMD, Gasdermin-D; eCasp-1, Extracellular caspase-1; DAMP, Damage-associated molecular pattern; TLR4, Toll-like receptor 4.

Journal: Frontiers in Immunology

Article Title: Extracellular caspase-1: a critical inducer and a therapeutic target of lung injury in gut ischemia-reperfusion

doi: 10.3389/fimmu.2026.1811868

Figure Lengend Snippet: Summary of findings. In gut I/R injury, inflammasomes activation promotes the cleavage of caspase-1 and the extracellular release of its p20 subunit through GSDMD-dependent membrane processes. This release may occur in association with GSDMD pore formation as well as membrane disruption during lytic cell death (pyroptosis). Once released, extracellular caspase-1 (eCasp-1) acts as a potent DAMP by binding to TLR4, thereby amplifying release of inflammatory cytokines, aggravating lung injury. Therapeutic intervention with the inhibitory peptide C16, which specifically blocks the eCasp-1-TLR4 interaction, effectively attenuates systemic inflammation and improves survival outcomes. I/R, Ischemia-reperfusion; GSDMD, Gasdermin-D; eCasp-1, Extracellular caspase-1; DAMP, Damage-associated molecular pattern; TLR4, Toll-like receptor 4.

Article Snippet: Recombinant mouse TLR4 (rmTLR4; ≥90% purity) was purchased from R&D Systems (Cat. No. 9149-TR-050, Minneapolis, MN), supplied in carrier-free form, and reconstituted in sterile PBS according to the manufacturer’s instructions.

Techniques: Activation Assay, Membrane, Disruption, Binding Assay

Nr-CWS affects MARCO expression through TLR4. The expression of TLR4 significantly increased after Nr-CWS treatment [ (D-G) , scale bars = 100 μm], while the expression TLR2 was unchanged (A-C) . Subsequent inhibition of TLR4 expression resulted in decreased levels of MARCO [ (H-J) , scale bars = 100 μm]. n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Frontiers in Immunology

Article Title: Nocardia rubra cell wall skeleton-induced MARCO expression: implications for improved phagocytosis and cytokine secretion in tumor-associated macrophages

doi: 10.3389/fimmu.2026.1611476

Figure Lengend Snippet: Nr-CWS affects MARCO expression through TLR4. The expression of TLR4 significantly increased after Nr-CWS treatment [ (D-G) , scale bars = 100 μm], while the expression TLR2 was unchanged (A-C) . Subsequent inhibition of TLR4 expression resulted in decreased levels of MARCO [ (H-J) , scale bars = 100 μm]. n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The following commercial antibodies (vendor, catalog number and dilution) utilized for western blot and immunohistochemical staining were employed in accordance with the manufacturers’ guidelines: mouse anti-CD68 antibody (Abcam, ab201340, 1:200), rabbit anti-MARCO antibody (Abcam, ab231046, 1:1000 for western blot and 1:100 for immunohistochemistry), rabbit anti-CD163 antibody (Abways Technology, CY6845, 1:500), mouse anti-CD86 antibody (Proteintech, 68674-2-Ig, 1:5000), mouse anti-TLR4 antibody (Santa Cruz Biotechnology, sc-293072, 1:1000 for western blot and 1:200 for immunohistochemistry), rabbit anti-TLR2 antibody(Abways Technology, CY5102, 1:2000), mouse anti-GAPDH antibody (Proteintech, 6004-1-Ig, 1:50000), HRP-goat anti-mouse recombinant secondary antibody (H+L)(Proteintech, RGAM001, 1:5000), goat anti-mouse IgG (H+L) Alexa Fluor 594 (Abways Technology, AB0152, 1:300), HRP-goat anti-rabbit recombinant secondary antibody (H+L) (Proteintech, RGAR001, 1:5000), goat anti-rabbit IgG (H+L) secondary antibody DyLightTM 594 (Report Biotech, S7002, 1:500), goat anti-mouse IgG (H+L) secondary antibody DyLightTM 488 (Report Biotech, S6001, 1:500), goat anti-mouse IgG (H+L) secondary antibody DyLightTM 594 (Abways Technology, AB0152, 1:500).

Techniques: Expressing, Inhibition

EA-induced analgesia is associated with MD2, TLR4, and p-p65/p65 in the ST36 acupoint and MD2 and TLR4 interactions. (A) The experimental protocol timeline is illustrated, with the duration of each intervention clearly indicated in the figure. (B) The location of the ST36 acupoint in mice (up) and the swelling of paw comparison before (right) and after (left) CFA injection. (C) PTWTs were detected on the D-3 to D-1, D1pre, D1post, D3, D5, and D7 after interventions (n = 8), ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM. (D) The expression levels of PKC protein in the spinal cord were determined by WB (n = 3), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (E, F) The expression levels of CX3CL1 (E) , IL-1β (F) in the spinal cord were determined by Elisa (n = 6), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (G) Data sourced from https://cn.string-db.org/ . (H) Co-IP assay with TLR4 antibody (or IgG) in the ST36 acupoint, followed by WB analysis of MD2 and TLR4. (I–K) The expression levels of MD2 (I) , TLR4 (J) , and p-p65/p65 (K) were determined using WB analysis in the ST36 acupoint on D7 (n = 3), * P < 0.05 vs. the CON, ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM.

Journal: Frontiers in Immunology

Article Title: Electroacupuncture alleviates pain by activating the MD2/TLR4/NF-κB pathway in the ST36 acupoint

doi: 10.3389/fimmu.2025.1626755

Figure Lengend Snippet: EA-induced analgesia is associated with MD2, TLR4, and p-p65/p65 in the ST36 acupoint and MD2 and TLR4 interactions. (A) The experimental protocol timeline is illustrated, with the duration of each intervention clearly indicated in the figure. (B) The location of the ST36 acupoint in mice (up) and the swelling of paw comparison before (right) and after (left) CFA injection. (C) PTWTs were detected on the D-3 to D-1, D1pre, D1post, D3, D5, and D7 after interventions (n = 8), ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM. (D) The expression levels of PKC protein in the spinal cord were determined by WB (n = 3), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (E, F) The expression levels of CX3CL1 (E) , IL-1β (F) in the spinal cord were determined by Elisa (n = 6), ** P < 0.01 vs. the CON, ** P < 0.01 vs. the SHAM. (G) Data sourced from https://cn.string-db.org/ . (H) Co-IP assay with TLR4 antibody (or IgG) in the ST36 acupoint, followed by WB analysis of MD2 and TLR4. (I–K) The expression levels of MD2 (I) , TLR4 (J) , and p-p65/p65 (K) were determined using WB analysis in the ST36 acupoint on D7 (n = 3), * P < 0.05 vs. the CON, ** P < 0.01 vs. the CON, ※※ P < 0.01 vs. the SHAM.

Article Snippet: Tissue lysate (1 mg protein) was incubated with either 2 μg of mouse monoclonal anti-TLR4 antibody or 2 μg of mouse IgG isotype control antibody (5415, Cell Signaling Technology, USA) for 1 hour at room temperature.

Techniques: Comparison, Injection, Expressing, Enzyme-linked Immunosorbent Assay, Co-Immunoprecipitation Assay

The effects of modulating MD2 in the ST36 acupoint on EA-induced analgesia and on the protein levels of MD2, TLR4, and p-p65/p65. (A) Lentivirus injection, behavioral testing, and acupoint stimulation experimental schedule. (B) Detection of lentivirus transduction in the ST36 acupoint by IF assay after MD2 knockdown lentivirus injection (n=3). (C) IF assay detection of lentivirus transduction in ST36 acupoint after overexpression lentivirus injection (n=3). (D) The transfection efficiency of the control lentivirus (FR-376) in ST36 acupoint (n=3). (E) The transfection efficiency of the control lentivirus (FV-115) in ST36 acupoint (n=3). (F) The expression of MD2 after injection of three different target knockdown lentiviruses were detected by WB (n=4). (G) The expression of MD2 after injection of overexpression was detected by WB (n=3). (H) The PTWTs were detected on D-3 to D-1, D1pre, D1post to D7 (every other day) (n = 6), ** P < 0.01 vs. the AIA+LVcon, # P < 0.05 vs. the AIA+LVcon+EA, ## P < 0.01 vs. the AIA+LVcon+EA. (I–K) The expression level of MD2 (I) , TLR4 (J) , and p-p65/p65 (K) (n = 3), ** P < 0.01 vs. the AIA+LVcon, # P < 0.05 vs. the AIA+LVcon+EA, ## P < 0.01 vs. the AIA+LVcon+EA. (L) PTWTs were detected on D-3 to D-1, D1pre, D1post to D7 (every other day) (n = 6), * P < 0.05 vs. the AIA+OEcon, ** P < 0.01 vs. the AIA+OEcon. (M–O) The expression level of MD2 (M) , TLR4 (N) , and p-p65/p65 (O) (n = 3), ** P < 0.01 vs. the AIA+OEcon.

Journal: Frontiers in Immunology

Article Title: Electroacupuncture alleviates pain by activating the MD2/TLR4/NF-κB pathway in the ST36 acupoint

doi: 10.3389/fimmu.2025.1626755

Figure Lengend Snippet: The effects of modulating MD2 in the ST36 acupoint on EA-induced analgesia and on the protein levels of MD2, TLR4, and p-p65/p65. (A) Lentivirus injection, behavioral testing, and acupoint stimulation experimental schedule. (B) Detection of lentivirus transduction in the ST36 acupoint by IF assay after MD2 knockdown lentivirus injection (n=3). (C) IF assay detection of lentivirus transduction in ST36 acupoint after overexpression lentivirus injection (n=3). (D) The transfection efficiency of the control lentivirus (FR-376) in ST36 acupoint (n=3). (E) The transfection efficiency of the control lentivirus (FV-115) in ST36 acupoint (n=3). (F) The expression of MD2 after injection of three different target knockdown lentiviruses were detected by WB (n=4). (G) The expression of MD2 after injection of overexpression was detected by WB (n=3). (H) The PTWTs were detected on D-3 to D-1, D1pre, D1post to D7 (every other day) (n = 6), ** P < 0.01 vs. the AIA+LVcon, # P < 0.05 vs. the AIA+LVcon+EA, ## P < 0.01 vs. the AIA+LVcon+EA. (I–K) The expression level of MD2 (I) , TLR4 (J) , and p-p65/p65 (K) (n = 3), ** P < 0.01 vs. the AIA+LVcon, # P < 0.05 vs. the AIA+LVcon+EA, ## P < 0.01 vs. the AIA+LVcon+EA. (L) PTWTs were detected on D-3 to D-1, D1pre, D1post to D7 (every other day) (n = 6), * P < 0.05 vs. the AIA+OEcon, ** P < 0.01 vs. the AIA+OEcon. (M–O) The expression level of MD2 (M) , TLR4 (N) , and p-p65/p65 (O) (n = 3), ** P < 0.01 vs. the AIA+OEcon.

Article Snippet: Tissue lysate (1 mg protein) was incubated with either 2 μg of mouse monoclonal anti-TLR4 antibody or 2 μg of mouse IgG isotype control antibody (5415, Cell Signaling Technology, USA) for 1 hour at room temperature.

Techniques: Injection, Transduction, Knockdown, Over Expression, Transfection, Control, Expressing

EA treatment can increase the co-expression of MD2/TLR4, TLR4-Vimentin, TLR4-Tryptase, as well as TLR4-F4/80 at the ST36 acupoint. (A) Double-labeling immunofluorescence of TLR4 (green), MD2 (red) and DAPI (blue), scale bar = 20 µm. (B) Double-labeling immunofluorescence of TLR4 (green), fibroblasts (red) and DAPI (blue), scale bar = 20 µm. (C) Double-labeling immunofluorescence of TLR4 (green) and Tryptase (red), scale bar = 20µm. (D) Double-labeling immunofluorescence of TLR4 (green) and F4/80 (red), DAPI (blue), scale bar = 20µm. (E) Immunofluorescence quantitative analysis of MD2/TLR4 (n = 3), * P < 0.05 vs. the CON, ## P < 0.01 vs. the AIA. (F) Immunofluorescence quantitative analysis of TLR4-Vimentin (n = 3), ** P < 0.01 vs. the CON, ## P < 0.01 vs. the AIA. (G) Immunofluorescence quantitative analysis of TLR4-Tryptase (n = 3), # P < 0.05 vs. the AIA. (H) Immunofluorescence quantitative analysis of TLR4-F4/80 (n = 3).

Journal: Frontiers in Immunology

Article Title: Electroacupuncture alleviates pain by activating the MD2/TLR4/NF-κB pathway in the ST36 acupoint

doi: 10.3389/fimmu.2025.1626755

Figure Lengend Snippet: EA treatment can increase the co-expression of MD2/TLR4, TLR4-Vimentin, TLR4-Tryptase, as well as TLR4-F4/80 at the ST36 acupoint. (A) Double-labeling immunofluorescence of TLR4 (green), MD2 (red) and DAPI (blue), scale bar = 20 µm. (B) Double-labeling immunofluorescence of TLR4 (green), fibroblasts (red) and DAPI (blue), scale bar = 20 µm. (C) Double-labeling immunofluorescence of TLR4 (green) and Tryptase (red), scale bar = 20µm. (D) Double-labeling immunofluorescence of TLR4 (green) and F4/80 (red), DAPI (blue), scale bar = 20µm. (E) Immunofluorescence quantitative analysis of MD2/TLR4 (n = 3), * P < 0.05 vs. the CON, ## P < 0.01 vs. the AIA. (F) Immunofluorescence quantitative analysis of TLR4-Vimentin (n = 3), ** P < 0.01 vs. the CON, ## P < 0.01 vs. the AIA. (G) Immunofluorescence quantitative analysis of TLR4-Tryptase (n = 3), # P < 0.05 vs. the AIA. (H) Immunofluorescence quantitative analysis of TLR4-F4/80 (n = 3).

Article Snippet: Tissue lysate (1 mg protein) was incubated with either 2 μg of mouse monoclonal anti-TLR4 antibody or 2 μg of mouse IgG isotype control antibody (5415, Cell Signaling Technology, USA) for 1 hour at room temperature.

Techniques: Expressing, Labeling, Immunofluorescence

The pattern of the effect of EA treatment on MD2, TLR4 in ST36 acupoint. (A) Behavioral testing, acupoint stimulation and molecular detection experimental schedule. (B–D) PTWTs were detected on D1post (B) (n=8), D3 (C) (n=6), and D5 (D) (n=6), ** P < 0.01 vs. the CON, ※ P < 0.05 vs. the SHAM, ※※ P < 0.01 vs. the SHAM. (E–H) The expression level of MD2 in the ST36 acupoint was determined by WB on D1post (E) , D3 (F) and D5 (G) (n = 3); the TLR4 was determined on the D5 (H) (n = 3), * P < 0.05 vs. the CON, ** P < 0.01 vs. the CON, # P < 0.05 vs. the AIA. ※ P < 0.05 vs. the SHAM.

Journal: Frontiers in Immunology

Article Title: Electroacupuncture alleviates pain by activating the MD2/TLR4/NF-κB pathway in the ST36 acupoint

doi: 10.3389/fimmu.2025.1626755

Figure Lengend Snippet: The pattern of the effect of EA treatment on MD2, TLR4 in ST36 acupoint. (A) Behavioral testing, acupoint stimulation and molecular detection experimental schedule. (B–D) PTWTs were detected on D1post (B) (n=8), D3 (C) (n=6), and D5 (D) (n=6), ** P < 0.01 vs. the CON, ※ P < 0.05 vs. the SHAM, ※※ P < 0.01 vs. the SHAM. (E–H) The expression level of MD2 in the ST36 acupoint was determined by WB on D1post (E) , D3 (F) and D5 (G) (n = 3); the TLR4 was determined on the D5 (H) (n = 3), * P < 0.05 vs. the CON, ** P < 0.01 vs. the CON, # P < 0.05 vs. the AIA. ※ P < 0.05 vs. the SHAM.

Article Snippet: Tissue lysate (1 mg protein) was incubated with either 2 μg of mouse monoclonal anti-TLR4 antibody or 2 μg of mouse IgG isotype control antibody (5415, Cell Signaling Technology, USA) for 1 hour at room temperature.

Techniques: Expressing